Health-Related Quality of Life of Adolescents With Non-transfusion-Dependent Thalassemia in Basrah, Iraq

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Oct 28

PMID 39463582

Authors

Zahraa M Hameed

Meaad K Hassan

Bahaa A Ahmed

Affiliations

Soon will be listed here.

Abstract

Background: Thalassemia is a chronic inherited disease with the potential for serious clinical and psychological effects. In the case of thalassemia, a cure is not currently accessible, and lifelong treatment is required. Health-related quality of life (HRQoL) is considered a crucial health outcome.

Objectives: This study aims to assess the HRQoL of children and adolescents with non-transfusion-dependent thalassemia (NTDT) and compare it with that of beta-thalassemia major (β-TM) and healthy subjects.

Patients And Methods: This case-control study included 88 patients with NTDT and 153 age- and gender-matched healthy children and adolescents. In addition, we included 70 registered patients with β-TM. We used the short-form health survey questionnaire to assess HRQoL.

Results: Of the 88 patients, 41 were diagnosed with alpha-thalassemia intermedia (α-TI; hemoglobin H disease), and 47 were with beta-thalassemia intermedia (β-TI). HRQoL domains were significantly higher in healthy children and adolescents compared to NTDT patients (P<0.001); the role emotion domain was the most affected in NTDT patients (51.92 ± 3.37), followed by general health (52.72 ± 3.05) and role physical (53.59 ± 3.13). α-TI patients had significantly higher HRQoL domains than patients with β-TI. The study also indicated that NTDT patients had significantly better QoL scores compared to β-TM patients (P<0.001) across all domains.

Conclusions: NTDT patients have a lower HRQoL compared to healthy controls. However, their HRQoL scores are significantly better than those of patients with β-TM. Among NTDT patients, those with α-TI have significantly better HRQoL scores compared to patients with β-TI.

References

Weatherall D . The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012; 26 Suppl 1:S3-6. DOI: 10.1016/S0268-960X(12)70003-6. View

Musallam K, Rivella S, Vichinsky E, Rachmilewitz E . Non-transfusion-dependent thalassemias. Haematologica. 2013; 98(6):833-44. PMC: 3669437. DOI: 10.3324/haematol.2012.066845. View

Abdulwahid D, Hassan M . β- and α-Thalassemia intermedia in Basra, Southern Iraq. Hemoglobin. 2013; 37(6):553-63. DOI: 10.3109/03630269.2013.825841. View

Ware Jr J . SF-36 health survey update. Spine (Phila Pa 1976). 2000; 25(24):3130-9. DOI: 10.1097/00007632-200012150-00008. View

Hakeem G, Mousa S, Moustafa A, Mahgoob M, Hassan E . Health-related quality of life in pediatric and adolescent patients with transfusion-dependent ß-thalassemia in upper Egypt (single center study). Health Qual Life Outcomes. 2018; 16(1):59. PMC: 5891954. DOI: 10.1186/s12955-018-0893-z. View

Taher A, Radwan A, Viprakasit V . When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. Vox Sang. 2014; 108(1):1-10. PMC: 4302976. DOI: 10.1111/vox.12201. View

Thavorncharoensap M, Torcharus K, Nuchprayoon I, Riewpaiboon A, Indaratna K, Ubol B . Factors affecting health-related quality of life in Thai children with thalassemia. BMC Blood Disord. 2010; 10:1. PMC: 2836992. DOI: 10.1186/1471-2326-10-1. View

Winichakoon P, Tantiworawit A, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E . Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia. Anemia. 2015; 2015:793025. PMC: 4667021. DOI: 10.1155/2015/793025. View

Fung E, Harmatz P, Lee P, Milet M, Bellevue R, Jeng M . Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol. 2006; 135(4):574-82. DOI: 10.1111/j.1365-2141.2006.06332.x. View

10.

Amin S, Jalal S, Ali K, Rasool L, Osman T, Ali O . Molecular Characterization and Disease-Related Morbidities of β-Thalassemia Patients from the Northeastern Part of Iraq. Int J Gen Med. 2020; 13:1453-1467. PMC: 7737013. DOI: 10.2147/IJGM.S277947. View

11.

Taher A, Musallam K, Cappellini M, Weatherall D . Optimal management of β thalassaemia intermedia. Br J Haematol. 2011; 152(5):512-23. DOI: 10.1111/j.1365-2141.2010.08486.x. View

12.

Musallam K, Khoury B, Abi-Habib R, Bazzi L, Succar J, Halawi R . Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol. 2011; 87(1):73-9. DOI: 10.1111/j.1600-0609.2011.01623.x. View

13.

Safizadeh H, Farahmandinia Z, Nejad S, Pourdamghan N, Araste M . Quality of life in patients with thalassemia major and intermedia in kerman-iran (I.R.). Mediterr J Hematol Infect Dis. 2012; 4(1):e2012058. PMC: 3499998. DOI: 10.4084/MJHID.2012.058. View

14.

Sobota A, Yamashita R, Xu Y, Trachtenberg F, Kohlbry P, Kleinert D . Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol. 2010; 86(1):92-5. PMC: 4250926. DOI: 10.1002/ajh.21896. View

15.

Bou-Fakhredin R, Bazarbachi A, Chaya B, Sleiman J, Cappellini M, Taher A . Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia. Int J Mol Sci. 2017; 18(12). PMC: 5751376. DOI: 10.3390/ijms18122778. View

16.

Guermazi M, Allouch C, Yahia M, Huissa T, Ghorbel S, Damak J . Translation in Arabic, adaptation and validation of the SF-36 Health Survey for use in Tunisia. Ann Phys Rehabil Med. 2012; 55(6):388-403. DOI: 10.1016/j.rehab.2012.05.003. View

17.

Pakbaz Z, Treadwell M, Yamashita R, Quirolo K, Foote D, Quill L . Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann N Y Acad Sci. 2005; 1054:457-61. DOI: 10.1196/annals.1345.059. View

18.

Mikael N, Al-Allawi N . Factors affecting quality of life in children and adolescents with thalassemia in Iraqi Kurdistan. Saudi Med J. 2018; 39(8):799-807. PMC: 6194984. DOI: 10.15537/smj.2018.8.23315. View

19.

Seyedifar M, Dorkoosh F, Hamidieh A, Naderi M, Karami H, Karimi M . Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran. Int J Hematol Oncol Stem Cell Res. 2016; 10(4):224-231. PMC: 5139942. View

20.

Vichinsky E . Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. Curr Med Res Opin. 2015; 32(1):191-204. DOI: 10.1185/03007995.2015.1110128. View